Why the study?
Antemortem diagnosis of pulmonary tumor embolism and pulmonary tumor thrombotic microangiopathy remains a clinical challenge due to their rapidly progressive nature.
PTE and PTTM are rare but fatal causes of rapidly progressive respiratory failure and tumoral pulmonary hypertension in patients with undiagnosed metastatic cancer.
Clinicians should consider PTE/PTTM in unexplained dyspnea with occult malignancy; leaves open spectrum validation and management strategies.
Pulmonary tumor embolism (PTE) and pulmonary tumor thrombotic microangiopathy (PTTM) are rare etiologies for rapidly progressive dyspnea in the setting of undiagnosed metastatic cancer. They occur most frequently in association with adenocarcinomas, with PTE being most frequently associated with hepatocellular carcinoma and PTTM being most commonly reported with gastric adenocarcinoma. Pulmonary tumor embolism and PTTM appear to be a disease spectrum where PTTM represents an advanced form of PTE. Pulmonary tumor embolism and PTTM are mostly identified postmortem during autopsy as the antemortem diagnosis remains a clinical challenge due to the rapidly progressive nature of these rare diseases. We report 2 cases of rapidly progressive respiratory failure leading to death, due to tumoral pulmonary hypertension resulting from PTE and PTTM, diagnosed postmortem. Both of the patients were middle-aged females, nonsmokers, and had a gastrointestinal source of their primary malignancy.
No takes yet. Share an insight, caveat, or question.
Rajdev et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: